Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

Shabsigh, Ridwan; Crawford, E. David; Nehra, Ajay; Slawin, Kevin M.

doi:10.1038/ijir.2008.31

Cited by 94 publications

(59 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Estudos selecionados nesta revisão também demonstraram que a taxa de incidência de CaP não aumentou e não houve progressão de PIN de alto grau para CaP em homens hipogonádicos tratados com TRT. Além disso, concentrações endógenas de testosterona sérica não estiveram associadas diretamente a mudanças anormais no PSA, e a TRT pareceu ser segura em homens tratados com intenção curativa para o CaP (36).…”

Section: Discussionunclassified

Câncer de próstata e testosterona: riscos e controvérsias

Rhoden

Averbeck²

2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOO hipogonadismo é uma síndrome clínica e bioquímica que pode estar associada a um prejuízo significativo na qualidade de vida (QoL) do homem. Com o aumento na expectativa de vida e sobrevida do câncer prostático (CaP), espera-se um número maior de diagnósticos de hipogonadismo em homens submetidos ao tratamento potencialmente curativo do CaP. Apesar da contraindicação clássica do emprego de terapia de reposição com testosterona (TRT) em homens com diagnóstico ou suspeita de CaP, não há evidência convincente de que a normalização dos níveis de testosterona séricos em homens com baixos níveis seja deletéria. Em poucas séries de casos que descreveram a TRT após o tratamento do CaP, não houve casos de progressão clínica ou bioquímica do tumor. Não obstante a literatura seja limitada, os dados disponíveis sugerem que a TRT pode ser considerada em homens hipogonádicos selecionados, previamente tratados curativamente para o CaP de baixo risco e sem evidência de doença ativa. Arq Bras Endocrinol Metab. 2009;53(8):956-62Descritores Neoplasia prostática; terapia de reposição de testosterona; prostatectomia radical; braquiterapia e câncer de próstata; tratamento de câncer de próstata ABSTRACTHypogonadism is a clinical and biochemical syndrome which may cause significant detriment in the quality of life. With the increase in life expectancy and prostate cancer survival a significant increase in the number of men with hypogonadism who have undergone presumably curative treatment for PCa is anticipated. Despite the widespread contraindication of testosterone in men with known or suspected prostate cancer, there is no convincing evidence that the normalization of testosterone serum levels in men with low, but not castrate levels, is deleterious. Although further studies are necessary before definitive conclusions can be drawn, the available evidence suggests that testosterone replacement therapy can be cautiously considered in selected hypogonadal men treated with curative intent for low risk prostate cancer and without evidence of active disease. Arq Bras Endocrinol Metab. 2009;53(8):956-62

show abstract

Section: Discussionunclassified

Câncer de próstata e testosterona: riscos e controvérsias

Rhoden

Averbeck²

2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…It is well established that testosterone therapy has no effect on the development of prostate cancer (5,25,38). However, there is testosterone peripheral conversion in dihydrotestosterone (DHT), which may stimulate prostate cells.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of late-onset hypogonadism (andropause) treatment using three different formulations of injectable testosterone

Hohl

Marques

Coral

et al. 2009

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: To compare the modalities of treatment for male hypogonadism available in Brazil. Methods: Thirty-two men with late-onset hypogonadism ("andropause") were followed-up in the Hospital de Guarnição de Florianópolis, in Florianópolis, south Brazil. Clinical diagnosis was established according to AMS questionnaire (positive if equal to or higher than 27 points), and laboratorial diagnosis was made through low values of total testosterone (under 300 ng/dL) and/or free calculated testosterone (under 6.5 ng/dL). Patients were randomized to three nonenteral treatment groups (Deposteron ® -11 patients; Durateston ® -11 patients; and Nebido ® -10 patients). Results: Clinically, Nebido ® seemed to be superior when compared to Deposteron ® (mean value of improvement percentage; p = 0.03) and when compared to Durateston ® (posttreatment average AMS score; p = 0.03). According to laboratorial analysis, Nebido ® showed higher testosterone levels than Deposteron ® and Durateston ® (p < 0.001). Conclusions: All nonenteral testosterone formulas available in the Brazilian market are efficient in raising testosterone levels and in clinical improvement of hypogonadal patients. Nebido ® showed both a better clinical and laboratorial effectiveness. Arq Bras Endocrinol Metab. 2009;53(8):989-96

show abstract

“…В ходе ис-следований было установлено, что гипогонадизм со-провождается низкой частотой развития рака пред-стательной железы, однако если он все же возникает у мужчин с гипогонадизмом, то отличается более агрессивными характеристиками, в том числе более высокой суммой Глисона [79]. Терапия тестостеро-ном не приводит к гистологическим изменениям предстательной железы или к значительному повы-шению содержания тестостерона и дигидротестосте-рона в предстательной железе [80,81]. Терапия тесто-стероном не повышает риск развития рака предста-тельной железы (уровень 2, степень B) [82,83].…”

Section: рак и доброкачественная гиперплазия предста-тельной железыunclassified

The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project

Дедов¹,

Мельниченко²,

Роживанов³

et al. 2015

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone which results in its low serum level in combination with characteristic clinical symptoms and/or signs (see the description below) that can be observed in the patients presenting with pathological changes in testicles and/or hypophysis, such as Kleinfelter’s syndrome, and in men with idiopathic metabolic or iatrogenic disorders leading to androgen deficiency. The present recommendations does not cover the entire set of pathological conditions responsible for the development of hypogonadism (deficit of testosterone); rather, they are focused on its clinical variants that account for the majority of the cases of male hypogonadism.

show abstract

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review

Cited by 94 publications

References 70 publications

Câncer de próstata e testosterona: riscos e controvérsias

Câncer de próstata e testosterona: riscos e controvérsias

Evaluation of late-onset hypogonadism (andropause) treatment using three different formulations of injectable testosterone

The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project

Contact Info

Product

Resources

About